We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+52.1%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.24B
AUM Growth
+$511M
Cap. Flow
-$50.3M
Cap. Flow %
-2.25%
Top 10 Hldgs %
66.48%
Holding
69
New
5
Increased
9
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$92.4M
2
ALGS icon
Aligos Therapeutics
ALGS
+$69.1M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$58.1M
4
TXG icon
10x Genomics
TXG
+$8.56M
5
ZLAB icon
Zai Lab
ZLAB
+$5.38M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$32.1M
2
ARWR icon
Arrowhead Research
ARWR
+$23.8M
3
SAGE
Sage Therapeutics
SAGE
+$21.6M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$21.6M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.89%
2 Financials 5.49%
3 Materials 3.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
51
AtriCure
ATRC
$2.01B
$3.6M 0.16%
64,573
– –
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
$3.36M 0.15%
585,394
-1,503,962
-72% -$11.4M
OVID icon
53
Ovid Therapeutics
OVID
$495M
$2.89M 0.13%
1,250,000
– –
IGMS
54
DELISTED
IGM Biosciences
IGMS
$1.77M 0.08%
20,000
-83,480
-81% -$5.87M
YARW
55
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$1.48M 0.07%
261
-245
-48% -$1.54M
TCDA
56
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.23M 0.06%
174,763
– –
DTIL icon
57
Precision BioSciences
DTIL
$205M
$1.17M 0.05%
4,675
– –
MTCR
58
DELISTED
Metacrine, Inc. Common Stock
MTCR
$1.15M 0.05%
146,426
– –
RVMD icon
59
Revolution Medicines
RVMD
$42.4B
$661K 0.03%
16,690
-82,827
-83% -$3.27M
LONA
60
LeonaBio Inc
LONA
$73.4M
– –
-30,000
Closed -$5.54M
BDTX icon
61
Black Diamond Therapeutics
BDTX
$110M
– –
-145,417
Closed -$4.4M
CVAC
62
DELISTED
CureVac
CVAC
– –
-169,825
Closed -$7.91M
ETNB
63
DELISTED
89bio
ETNB
– –
-183,042
Closed -$4.7M
KNSA icon
64
Kiniksa Pharmaceuticals
KNSA
$5.97B
– –
-1,151,622
Closed -$17.6M
LITS
65
Lite Strategy Inc
LITS
$31.6M
– –
-40,848
Closed -$2.55M
RNAC icon
66
Cartesian Therapeutics
RNAC
$265M
– –
-31,573
Closed -$2.35M
SAGE
67
DELISTED
Sage Therapeutics
SAGE
– –
-353,511
Closed -$21.6M
TECX
68
Tectonic Therapeutic
TECX
$570M
– –
-17,185
Closed -$2.69M
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-158,310
Closed -$21.6M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Vivo Capital held 69 positions worth $2.24B, up 30% from $1.73B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Vivo Capital's Q4 2020 filing shows 5 new, 9 increased, 19 reduced and 10 closed positions. Its largest new stake was Tarsus Pharmaceuticals: 3,245,035 shares worth $134M. The largest sale was Immunovant, an estimated $32.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q4 2020 buy was Tarsus Pharmaceuticals: 3,245,035 shares worth $134M.
  • Vivo Capital added most to Zai Lab in Q4 2020, an estimated $5.38M increase.
  • Vivo Capital's biggest Q4 2020 reduction was Immunovant, cutting an estimated $32.1M.
  • Vivo Capital fully exited Sage Therapeutics in Q4 2020, selling an estimated $21.6M.
  • Vivo Capital's ten largest holdings make up 66% of its $2.24B portfolio in Q4 2020.
  • Vivo Capital opened 5 new positions and closed 10 in Q4 2020.
  • Vivo Capital's portfolio value rose 30% quarter-over-quarter to $2.24B.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.